

# WORKSHOP: TOWARDS USEFUL CANCER BIOMARKERS

Suggestions	Who must be involved	Who can initiate?
Incentivise predictive biomarker discovery: a business model	Payers/authorities like TLV, NICE	Pharma, patient advocacy groups, founders/philantropy
Interact with the regulators <u>early</u>	Academia, biotech/pharma, regulators (EMA, FDA)	Academia, biotech/pharma
Clear guidelines for biomarker performance	Regulators	Regulators
Clear guidelines for academic biomarker discovery studies	Academia	Founders
Mechanism to prioritize by need (QALY etc)	Academia, regulators, payers	Academia, patient advocacy groups

# WORKSHOP: TOWARDS USEFUL CANCER BIOMARKERS

	How will this: ...contribute to more <u>efficient</u> cancer care?	... contribute to more <u>equal</u> cancer care?	... improve the individual patient's <u>quality of life</u> ?	... influence which <u>health decisions</u> the patient and her kin can make?
Incentivise predictive biomarker discovery/Interact with regulators <u>early</u>	Right drug to right patient	Resource reallocation to patients most in need: more affordable care	Less side effects, more effect	Informed choice of care
Clear guidelines for biomarker performance	More accurate = useful biomarkers		More informed clinical decisions	
Prioritize development by need	Biomarkers for diseases that currently lack	Resource reallocation to patients most in need: more affordable care	Less invasive diagnostics, biomarkers for early discovery	